Overview

A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer

Status:
Recruiting

Trial end date:
2021-10-31

Target enrollment:

Participant gender:

Summary

This is a Phase II, multicenter，randomized, two arms, open-labeled, controlled clinical trial. This trial was conducted to evaluate the efficacy and safety of bevacizumab (Avastin®) plus mXELIRI compared with bevacizumab (Avastin®) plus FOLFIRI as first-line treatment in patients with metastatic colorectal cancer (mCRC).

Phase:

Phase 2

Details

Lead Sponsor:

Chinese Academy of Medical Sciences

Collaborators:

Beijing Hospital
Henan Cancer Hospital
Jiangsu Cancer Institute & Hospital
Liaoning Tumor Hospital & Institute

Treatments:

Bevacizumab
Capecitabine
Fluorouracil
Irinotecan